Company
DanausGT Biotech is a global company focused on the usage of gene editing technology and cell therapy to treat a wide range of diseases. The company has independent intellectual property rights of CRISPR/AAV technology platform, which can achieve precise gene replacement to completely cure patients, editing efficiency of up to 80%, and is constantly improving. At present, several projects are simultaneously in the stages from preclinical to clinical Phase I. Among them, the pyruvate kinase deficiency pipeline CG001 obtained EMA orphan drug designation in March 2022, and is expected to complete the IND application in Europe and the United States by mid-2023.
Description
DanausGT Biotech platform achieves precise gene replacement and expands the global rare disease market.
